| Homozygous Familial Hypercholesterolemia
Juxtapid vs Praluent
Side-by-side clinical, coverage, and cost comparison for homozygous familial hypercholesterolemia.Deep comparison between: Juxtapid vs Praluent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPraluent has a higher rate of injection site reactions vs Juxtapid based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Praluent but not Juxtapid, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Juxtapid
Praluent
At A Glance
Oral
Daily
MTP inhibitor
SC injection
Every 2-4 weeks
PCSK9 inhibitor
Indications
- Homozygous Familial Hypercholesterolemia
- Myocardial Infarction
- Coronary heart disease
- Cerebrovascular accident
- Angina, Unstable
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
Dosing
Homozygous Familial Hypercholesterolemia Initiate at 5 mg once daily with water, without food, at least 2 hours after the evening meal; titrate to 10 mg after at least 2 weeks, then at minimum 4-week intervals to 20 mg, 40 mg, and up to 60 mg daily maximum; patients with ESRD on dialysis or mild hepatic impairment (Child-Pugh A) should not exceed 40 mg daily.
Hypercholesterolemia, Myocardial Infarction, Coronary heart disease, Cerebrovascular accident, Angina, Unstable 75 mg SC once every 2 weeks or 300 mg SC once every 4 weeks; may adjust to 150 mg SC every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (adults on LDL apheresis), Homozygous Familial Hypercholesterolemia 150 mg SC once every 2 weeks; may be administered without regard to timing of LDL apheresis.
Familial hypercholesterolemia - heterozygous (pediatric, <50 kg) 150 mg SC once every 4 weeks; may adjust to 75 mg SC once every 2 weeks if LDL-C response is inadequate.
Familial hypercholesterolemia - heterozygous (pediatric, >=50 kg) 300 mg SC once every 4 weeks; may adjust to 150 mg SC once every 2 weeks if LDL-C response is inadequate.
Contraindications
- Pregnancy
- Concomitant use of moderate or strong CYP3A4 inhibitors
- Moderate or severe hepatic impairment (Child-Pugh B or C) or active liver disease, including unexplained persistent elevations of serum transaminases
- Previous serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT
Adverse Reactions
Most common (>=28%) Diarrhea, nausea, vomiting, dyspepsia, abdominal pain
Serious Hepatotoxicity, increased ALT
Postmarketing Myalgia, alopecia
Most common (>=2%) Injection site reactions, influenza, diarrhea, myalgia, muscle spasms, contusion
Serious Hypersensitivity vasculitis, nummular eczema, angioedema
Postmarketing Angioedema, influenza-like illness
Pharmacology
MTP inhibitor; lomitapide directly binds and inhibits microsomal triglyceride transfer protein (MTP) in the endoplasmic reticulum, preventing assembly of apo B-containing lipoproteins in enterocytes and hepatocytes, thereby inhibiting synthesis of chylomicrons and VLDL and reducing plasma LDL-C.
Alirocumab is a human monoclonal antibody that inhibits PCSK9, a protein that promotes LDL receptor degradation on hepatocytes, thereby increasing LDL receptor availability and lowering circulating LDL-C levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Juxtapid
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Praluent
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Juxtapid
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (0/8)
Praluent
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Juxtapid
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Praluent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Hypercholesterolemia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$50/momo
MyPraluent Copay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
JuxtapidView full Juxtapid profile
PraluentView full Praluent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.